Evidence map›Paper›PMID 36387066›Full record

ArticleFrontiers in oncology2022

Corrigendum: OIT3 serves as a novel biomarker of hepatocellular carcinoma by mediating ferroptosis

Jie Wen, Abudureyimujiang Aili, Yao Xue Yan, YuLin Lai, Shaoqing Niu, Shasha He, Xiaokai Zhang, Guixiong Zhang, Jiaping Li

Open access · goldAbstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.1field-weighted citation impact, top 59% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Jie WenDepartment of Interventional Oncology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China and Department of Medical Oncology and Radiation Sickness, Peking University Third Hospital, Beijing, China.
Abudureyimujiang AiliDepartment of Medical Oncology and Radiation Sickness, Peking University Third Hospital, Beijing, China.
Yao Xue YanDepartment of Dermatology, Peking University People's Hospital, Beijing, China.
YuLin LaiDeparment of Radiotherapy, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Shaoqing NiuDeparment of Radiotherapy, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Shasha HeDeparment of Radiotherapy, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Xiaokai ZhangDepartment of Interventional Oncology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Guixiong ZhangDepartment of Interventional Oncology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Jiaping LiDepartment of Interventional Oncology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Sun Yat-sen University · CNPeking University People's Hospital · CNPeking University Third Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

[This corrects the article DOI: 10.3389/fonc.2022.977348.].

Indexed as

arachidonic acidbiomarkerferroptosisHCCOIT3

Identifiers

PMID36387066
PMCPMC9645243
OpenAlexW4307550903

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.